Trial Profile
Biodistribution and pharmacokinetics, safety and therapeutic effect of the CIGB-300 application in the epidermoid carcinoma of the uterine neck stage IB2-II
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Oct 2020
Price :
$35
*
At a glance
- Drugs CIGB 300 (Primary)
- Indications Cervical cancer
- Focus Pharmacokinetics
- Acronyms CERVIFARM-300-II
- 23 Dec 2013 Status changed from active, no longer recruiting to completed as reported by Cuban Clinical Trial Registry record
- 18 Feb 2013 New trial record